@luv4ucuts: Wish 3rd Aniversary! Fanchant frames coming late>< #nctwish #photobooth #frame #DIY #tutorial #sion #sakuya #ryo #riku #yushi #jaehee #kpopfyp #fyp

Luv4Ucuts
Luv4Ucuts
Open In TikTok:
Region: US
Saturday 28 February 2026 03:32:31 GMT
41038
3344
19
224

Music

Download

Comments

whopwhop_21
apahaikamu :
NCT DREAM PLEASSS
2026-02-28 13:35:59
3
gigii1995
Gisela Estevez :
Seonghwa please!!!
2026-03-02 06:11:05
2
cr0i8antt
meyyziiiaayyy :
lucuuu
2026-03-28 00:19:15
15
yushi_me3
𝑆𝑎𝑘𝑢໒꒱ 🥐 :
Is it free? 💞
2026-05-14 05:36:19
0
shindydy
shin :
yushi riku pls😭😭😭
2026-04-09 11:13:29
0
cheetouzz
sya ₊˚⊹♡ :
LUCU BANGEEETTTTTT
2026-04-05 11:08:13
0
yvwanlta
🌱uanita💨 :
sakuya plis
2026-03-20 16:19:25
0
ow.its.yoongi
𝒯𝐚𝐢𝐞𝐥 𝕃ℴ𝕧ℯ 𝒉𝖺𝒕𝗂 :
Amg faz tut
2026-02-28 20:24:21
0
xuihao_sa
에잇🐸 :
cara print nya gimana kak
2026-03-02 00:39:55
0
rikukittizcharlotz
rikukittiz ʚଓ :
@JunhanLover @cresselia @Ahhneemaeh someone do it pls
2026-05-04 18:05:08
3
julstaaa
Ju🇮🇹 :
🥰🥰🥰
2026-04-26 01:01:27
0
To see more videos from user @luv4ucuts, please go to the Tikwm homepage.

Other Videos

Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close.   Note: I have not been compensated in any way for this post/interview.  #Foundayo #newGLP-1 #GLP-1pill #EliLilly
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly

About